FDA approves new drug market ingenues for Mercadobacteria therapy Zerbaxa (ceftolozane/tazobactam)
-
Last Update: 2020-06-09
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
hospital acquired/respirator-related bacterial pneumonia (HABP/VABP) is a type of pneumonia that is susceptible to in-hospital and othermedical(http://institutions, and causes a variety of different bacteriaAccording to the U.SCenters for Disease Control and Prevention (CDC), HABP/VABP is currently the second most common hospital infection in the United StatesIn severe cases, it can even take the patient's lifetoday, MSD announced that its supplementarynew drug(http://market application (http:// for its antimicrobial treatment Zerbaxa (ceftolozane/tazobactam) has been approved by the U.SFDA(http://for the treatment of patients with specific bacterial pneumonia ages 18 and olderZerbaxa
Zerbaxa is an antibiotic combination product (http:// that includes cephalosporine antibioticce ceftolozane and beta-lactamase inhibitor tazobactam It is expected to treat a variety of Gram-negative bacteria that cause HABP/VABP In a Phase 3 clinical trial (http:// , researchers recruited 726 HABP/VABP patients studies have shown that Zerbaxa is not bad ewhat, compared to the broad-spectrum antibiotic merlopem, and can therefore be used as a new treatment for this population previously, the therapy has also been eligible for qualified infectious disease products (QIDP) and priority review spree spree spree spree spree
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
